Carl Maximilian Thielmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carl Maximilian Thielmann has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Schadendorf
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
10 shared publications - Georg Lodde
Department of Dermatology, University Hospital Essen, Essen, Germany
8 shared publications - Klaus Georg Griewank
Department of Dermatology, Venereology and Allergology, University Hospital Essen , Essen
8 shared publications - Lisa Zimmer
Dermatology, University of Duisburg-Essen, Essen, Germany
8 shared publications - Antje Sucker
University Hospital Essen 1 Essen
7 shared publications - Eva Hadaschik
Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany
7 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Mutational landscape in cutaneous melanoma
- 22 October 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Open AccessMutational landscape in cutaneous melanoma
- Open Access
- 30 June 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment
- 30 June 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Open AccessSingle-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment
- Open Access
- 22 March 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
PD-L1 assessment in Merkel cell carcinoma: Predictive implications for anti-PD-1 and anti-PD-L1 therapy
- 22 March 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Open AccessPD-L1 assessment in Merkel cell carcinoma: Predictive implications for anti-PD-1 and anti-PD-L1 therapy
- Open Access
- 3 March 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 220, 115337
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy
- 3 March 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 220, 115337
Open AccesspTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy
- Open Access
- 20 January 2024
- Published by Wiley in JEADV Clinical Practice
- Vol. 3 (3) , 887-890
Tinea capitis due to Trichophyton soudanense and Microsporum audouinii: A surprising finding
Tinea capitis is a prevalent dermatophyte infection among German children, primarily caused by Microsporum canis, Trichophyton mentagrophytes and Trichophyton benhamiae. Other pathogens, such as T. soudanense and M. audouinii, have also been identified in Germany. This case report describes a 10‐year‐old Angolan girl with chronic osteomyelitis who was brought to Germany for treatment, which was organized by the Friedensdorf International (Peacevillage International). In addition to chronic osteomyelitis of the lower leg, the patient presented with alopecic areas of the scalp with adherent scales, which raised the suspicion of tinea capitis. Fungal cultivation and polymerase chain reaction (PCR) diagnostics revealed a coinfection of T. soudanense and M. audouinii, which, to the best of our knowledge, has not been previously reported in Europe. After 4 weeks of systemic terbinafine treatment and topical use of ciclopirox solution and clotrimazole cream, there was a marked improvement in the patient's condition. This was confirmed by a negative fungal culture and PCR; no adverse events were reported. This report highlights a rare dual dermatophyte infection caused by T. soudanense and M. audouinii in Europe, and the successful response to treatment with systemic terbinafine and topical ciclopirox solution as well as clotrimazole cream.
- 20 January 2024
- Published by Wiley in JEADV Clinical Practice
- Vol. 3 (3) , 887-890
Open AccessTinea capitis due to Trichophyton soudanense and Microsporum audouinii: A surprising finding
Tinea capitis is a prevalent dermatophyte infection among German children, primarily caused by Microsporum canis, Trichophyton mentagrophytes and Trichophyton benhamiae. Other pathogens, such as T. soudanense and M. audouinii, have also been identified in Germany. This case report describes a 10‐year‐old Angolan girl with chronic osteomyelitis who was brought to Germany for treatment, which was organized by the Friedensdorf International (Peacevillage International). In addition to chronic osteomyelitis of the lower leg, the patient presented with alopecic areas of the scalp with adherent scales, which raised the suspicion of tinea capitis. Fungal cultivation and polymerase chain reaction (PCR) diagnostics revealed a coinfection of T. soudanense and M. audouinii, which, to the best of our knowledge, has not been previously reported in Europe. After 4 weeks of systemic terbinafine treatment and topical use of ciclopirox solution and clotrimazole cream, there was a marked improvement in the patient's condition. This was confirmed by a negative fungal culture and PCR; no adverse events were reported. This report highlights a rare dual dermatophyte infection caused by T. soudanense and M. audouinii in Europe, and the successful response to treatment with systemic terbinafine and topical ciclopirox solution as well as clotrimazole cream.
- Open Access
- 15 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (24) , 7432
Myocardial Injury Is Associated with the Incidence of Major Adverse Cardiac Events in Patients with Severe Trauma
Background: Severe trauma potentially results in end-organ damage such as myocardial injury. Data suggest that myocardial injury is associated with increased mortality in this cohort, but the association with the incidence of in-hospital major adverse cardiac events (MACE) remains undetermined. Methods: Retrospective cohort study including adult patients with severe trauma treated at the University Hospital Duesseldorf between January 2016 and December 2019. The main exposure was myocardial injury at presentation. Endpoints were in-hospital incidence of MACE and incidence of acute kidney injury (AKI) within 72 h. Discrimination of hsTnT for MACE and AKI was examined by the receiver operating characteristic curve (ROC) and the area under the curve (AUC). We conducted multivariate logistic regression analysis. Results: We included 353 patients in our final analysis (72.5% male (256/353), age: 55 ± 21 years). The AUC for hsTnT and MACE was 0.68 [95% confidence interval (CI): 0.59–0.78]. The AUC for hsTnT and AKI was 0.64 [95% (CI): 0.55–0.72]. The adjusted odds ratio (OR) for myocardial injury and MACE was 2.97 [95% (CI): 1.31–6.72], and it was 2.14 [95% (CI): 1.03–4.46] for myocardial injury and AKI. Conclusion: Myocardial injury at presentation in patients with severe trauma is independently associated with the incidence of in-hospital MACE and AKI.
- 15 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (24) , 7432
Open AccessMyocardial Injury Is Associated with the Incidence of Major Adverse Cardiac Events in Patients with Severe Trauma
Background: Severe trauma potentially results in end-organ damage such as myocardial injury. Data suggest that myocardial injury is associated with increased mortality in this cohort, but the association with the incidence of in-hospital major adverse cardiac events (MACE) remains undetermined. Methods: Retrospective cohort study including adult patients with severe trauma treated at the University Hospital Duesseldorf between January 2016 and December 2019. The main exposure was myocardial injury at presentation. Endpoints were in-hospital incidence of MACE and incidence of acute kidney injury (AKI) within 72 h. Discrimination of hsTnT for MACE and AKI was examined by the receiver operating characteristic curve (ROC) and the area under the curve (AUC). We conducted multivariate logistic regression analysis. Results: We included 353 patients in our final analysis (72.5% male (256/353), age: 55 ± 21 years). The AUC for hsTnT and MACE was 0.68 [95% confidence interval (CI): 0.59–0.78]. The AUC for hsTnT and AKI was 0.64 [95% (CI): 0.55–0.72]. The adjusted odds ratio (OR) for myocardial injury and MACE was 2.97 [95% (CI): 1.31–6.72], and it was 2.14 [95% (CI): 1.03–4.46] for myocardial injury and AKI. Conclusion: Myocardial injury at presentation in patients with severe trauma is independently associated with the incidence of in-hospital MACE and AKI.
- Open Access
- 14 September 2022
- Published by Wiley in JEADV Clinical Practice
- Vol. 1 (4) , 416-419
Giant congenital melanocytic naevus caused by NRAS Q61K mosaicism
Giant congenital melanocytic naevi (CMN) are large melanocytic lesions commonly associated with neurologic abnormalities. Patients diagnosed with giant melanocytic naevi are at an increased risk of developing melanoma compared to patients with smaller congenital naevi. If patients develop central nervous system (CNS) lesions and exhibit certain characteristic facial features, then the diagnosis of CMN syndrome can be made. We here present the case of a 24‐year‐old female who presented with multiple melanocytic naevi, which had been apparent since birth, and was diagnosed with giant melanocytic naevi caused by NRAS Q61K mosaicism. Both close follow‐up of imaging and clinical study is important so as not to miss cutaneous malignancy and CNS lesions.
- 14 September 2022
- Published by Wiley in JEADV Clinical Practice
- Vol. 1 (4) , 416-419
Open AccessGiant congenital melanocytic naevus caused by NRAS Q61K mosaicism
Giant congenital melanocytic naevi (CMN) are large melanocytic lesions commonly associated with neurologic abnormalities. Patients diagnosed with giant melanocytic naevi are at an increased risk of developing melanoma compared to patients with smaller congenital naevi. If patients develop central nervous system (CNS) lesions and exhibit certain characteristic facial features, then the diagnosis of CMN syndrome can be made. We here present the case of a 24‐year‐old female who presented with multiple melanocytic naevi, which had been apparent since birth, and was diagnosed with giant melanocytic naevi caused by NRAS Q61K mosaicism. Both close follow‐up of imaging and clinical study is important so as not to miss cutaneous malignancy and CNS lesions.
- Open Access
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival
(1) Background: Melanoma has the highest mortality of all cutaneous tumors, despite recent treatment advances. Many relevant genetic events have been identified in the last decade, including recurrent ARID1A mutations, which in various tumors have been associated with improved outcomes to immunotherapy. (2) Methods: Retrospective analysis of 116 melanoma samples harboring ARID1A mutations. Assessment of clinical and genetic characteristics was performed as well as correlations with treatment outcome applying Kaplan–Meier (log-rank test), Fisher’s exact and Chi-squared tests. (3) Results: The majority of ARID1A mutations were in cutaneous and occult melanoma. ARID1A mutated samples had a higher number of mutations than ARID1A wild-type samples and harbored UV-mutations. A male predominance was observed. Many samples also harbored NF1 mutations. No apparent differences were noted between samples harboring genetically inactivating (frame-shift or nonsense) mutations and samples with other mutations. No differences in survival or response to immunotherapy of patients with ARID1A mutant melanoma were observed. (4) Conclusions: ARID1A mutations primarily occur in cutaneous melanomas with a higher mutation burden. In contrast to findings in other tumors, our data does not support ARID1A mutations being a biomarker of favorable response to immunotherapies in melanoma. Larger prospective studies would still be warranted.
Open AccessGenetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival
(1) Background: Melanoma has the highest mortality of all cutaneous tumors, despite recent treatment advances. Many relevant genetic events have been identified in the last decade, including recurrent ARID1A mutations, which in various tumors have been associated with improved outcomes to immunotherapy. (2) Methods: Retrospective analysis of 116 melanoma samples harboring ARID1A mutations. Assessment of clinical and genetic characteristics was performed as well as correlations with treatment outcome applying Kaplan–Meier (log-rank test), Fisher’s exact and Chi-squared tests. (3) Results: The majority of ARID1A mutations were in cutaneous and occult melanoma. ARID1A mutated samples had a higher number of mutations than ARID1A wild-type samples and harbored UV-mutations. A male predominance was observed. Many samples also harbored NF1 mutations. No apparent differences were noted between samples harboring genetically inactivating (frame-shift or nonsense) mutations and samples with other mutations. No differences in survival or response to immunotherapy of patients with ARID1A mutant melanoma were observed. (4) Conclusions: ARID1A mutations primarily occur in cutaneous melanomas with a higher mutation burden. In contrast to findings in other tumors, our data does not support ARID1A mutations being a biomarker of favorable response to immunotherapies in melanoma. Larger prospective studies would still be warranted.
- 10 March 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 166, 60-72
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
- 10 March 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 166, 60-72
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment